Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Withdrawn × NIH × Clonidine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms, Second Primary 1 Neoplasms 1

Interventions

Specimen Handling 11 Magnetic Resonance Spectroscopy 10 Cyclophosphamide 9 Nivolumab 6 Drug Therapy 6 Dexamethasone 6 Biopsy 6 Biological Therapy 6 fludarabine 5 aldesleukin 5 Ipilimumab 5 Doxorubicin 5 antineoplaston AS 2-1 4 antineoplaston A10 4 Rituximab 4 Etoposide 4 Complementary Therapies 4 Cisplatin 4 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 4 olaparib 3 copanlisib 3 atezolizumab 3 X-Rays 3 Vincristine 3 Surgical Procedures, Operative 3 Phantoms, Imaging 3 Fluorouracil 3 Filgrastim 3 Chemotherapy, Adjuvant 3 CTLA-4 Antigen 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00166686 2013-01-11

Clonidine for Neurocognitive Sequelae

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Phase 1/2 Withdrawn

Neoplasms, Neoplasms, Second Primary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡